Email ID
Password
Scrip   
Osiris's stem cells fail two phase III trials in GvHD
09 September 2009
Asher Mullard

Osiris Therapeutics's stem cell treatment Prochymal has failed to improve complete response rates in two late-stage trials for graft versus host disease (GvHD) – one in newly-diagnosed GvHD and the other in steroid-refractory GvHD. While Osiris emphasised its product's success in treating a subset...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36